STENOCARE – Final deadline Soon for Subscription to New Shares at DKK 0.50 Each
STENOCARE A/S
NASDAQ FIRST NORTH GROWTH MARKET, DENMARK
TICKER: STENO
STENOCARE A/S (“Stenocare” or the "Company") began on January 07 the subscription period for investors to subscribe for new shares at a discounted price of DKK 0.50 each. The final deadline for this time limited offer is January 20, 2025, and owners of subscription rights should decide how to use these rights and new investors should decide if they like to subscribe using the online subscription form.
Stenocare has announced a time limited offer to subscribe for new shares in the Company at a discounted price of DKK 0.50 per share. The Company is seeking to raise between DKK 9.1 million and DKK 20.2 million to execute the STENOCARE 3.0 strategy.
The time for trading subscription rights ended January 16, and therefore investors have three options to consider before January 20, 2025, at 5:00 PM Copenhagen time:
- Owners of subscription rights need to decide if they like to use these rights for subscribing (ie. Purchasing) the new shares at the discounted price of DKK 0,50 per share. To do this, the investor needs to instruct their bank to use the subscription rights before the deadline. Please notice some bank might have a shorter deadline.
- New investors should use the online subscription form in their bank or use the official Subscription Form to instruct their bank to subscribe for the offer. Complete the form and send it to the bank. Please notice some bank might have a shorter deadline.
- Both owners of subscription rights and new investors can decide not to participate in the Rights Issue with a subscription for new shares. The subscription rights not used for subscription of new shares will be void.
All the details are available on the investor homepage: https://stenocare.com/share-issue-2025/
To read the official announcement of the conditional rights issue: https://stenocare.com/investor-relations/announcements/3B051C92836EB553/
Who are Stenocare?
Stenocare is a Danish company that has specialised in trading with prescription-based medical cannabis products. The Company has sales activities in 6 different countries with medical cannabis products approved for sales by the local medicine agencies. Stenocare has just launched a new and innovative product, called ASTRUM 10-10, that has the potential to revolutionise the medical cannabis industry. This new patented product has been approved for sales in Germany, Australia and Norway.
For additional information regarding STENOCARE, please contact:
Thomas Skovlund Schnegelsberg, CEO Phone: +45 31770060 E-mail: presse@stenocare.com
About STENOCARE A/S
STENOCARE A/S, founded in 2017, supplies prescription-based medical cannabis to patients in Denmark and internationally. It was the first company to receive permission from the Danish Medicines Agency to import, distribute, cultivate, and produce medical cannabis. Today, STENOCARE sources its products from a selection of high-quality international suppliers that comply with the strict European Good Manufacturing Practices (EU-GMP). STENOCARE has developed a unique patented medical cannabis oil product, ASTRUM, which provides improved bioavailability of active ingredients for patients. The company has strategically invested in assets to operate within the highly regulated pharmaceutical industry, with products approved for sale in multiple countries.
www.stenocare.com www.stenocare.dk www.stenocare.se